Outlook Therapeutics, Inc. (OTLK)

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Oncobiologics Q3 Earnings Call Highlights

Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Oncobiologics Q3 Earnings Call Highlights

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs

US FDA approves Outlook Therapeutics' eye disease drug

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review

Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time